G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

NCT03455270 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Ductal, Breast
Breast Cancer Female
Breast Neoplasm
Breast Cancer
Metastatic Breast Cancer
Advanced Breast Cancer
Stage IV Breast Cancer

Interventions

DRUG: G1T48
DRUG: Palbociclib

Sponsor

G1 Therapeutics, Inc.